Pomerantz Law Firm Issues Investor Alert on TransMedics Group Inc. Class Action Lawsuit

Investors Take Note: Class Action Lawsuit Against TransMedics Group, Inc.

On March 31, 2025, Pomerantz LLP, a leading law firm in securities class litigation, announced a class action lawsuit against TransMedics Group, Inc. (NASDAQ: TMDX). This action has emerged as a response to alarming allegations concerning inappropriate business practices within the company, thereby putting the interests of its investors at risk.

If you are one of the investors who have seen losses due to your investment in TransMedics, it's crucial to act promptly. The law firm is calling on investors to get in touch with their representatives, specifically Danielle Peyton at [email protected], or by phone at 646-581-9980, and even offers a toll-free hotline at 888.4-POMLAW. To assist in addressing your claim, mention your mailing address, phone number, and the number of shares purchased during your inquiry.

The allegations against TransMedics are severe. Reports suggest that the company and certain high-ranking officials may have engaged in securities fraud and unlawful business practices. This has raised considerable concern in the investor community and calls into question the integrity of the company’s stock performance.

Investors who purchased or acquired TransMedics securities during the specified class period have until April 15, 2025, to request the court appoint them as the Lead Plaintiff. Detailed information regarding the case, including a copy of the complaint, can be found on Pomerantz’s official website at www.pomerantzlaw.com.

The impetus for this legal action stems from recent accusations by U.S. Representative Paul Gosar, who has voiced concerns over alleged corporate misconduct. In a letter issued on February 21, 2024, he outlined serious allegations against TransMedics, including claims of resource misappropriation. Following these revelations, the company’s stock experienced a notable decline, shedding $3.85 or approximately 4.43% over just two trading sessions, concluding at $83.14 per share on February 23, 2024.

Adding to the tumult, a report released by Scorpion Capital on January 10, 2025, elaborated on potentially fraudulent activities concerning the company’s billing practices and off-label misuse of its medical devices. This report intensified scrutiny around TransMedics as it detailed ongoing investigations from the U.S. Department of Justice and other state agencies regarding alleged Medicare fraud related to organ acquisition costs. Furthermore, the report highlighted an unsettling trend of customer dissatisfaction, with esteemed transplant centers reportedly ceasing the use of TransMedics devices due to concerns regarding their clinical effectiveness.

In response to these revelations, the stock price of TransMedics plummeted once again, dropping $3.74 or 5.16%, closing at $68.81 per share on January 10, 2025.

Pomerantz LLP brings over 85 years of experience in corporate and securities law. Founded by the late Abraham L. Pomerantz, often referred to as the dean of the class action bar, the firm has a long-standing tradition of advocating for victims of financial fraud and corporate misconduct. Their efforts have led to substantial monetary recoveries for class members in the past.

Given the gravity of the situation, affected investors should consider the potential implications of these allegations on their investments and leverage the opportunity presented by the class action. Attorney advertising applies to this announcement, and past success does not guarantee similar results in the future.

In conclusion, if you are an investor in TransMedics, pay attention to the upcoming deadlines and safeguard your rights by reaching out to Pomerantz LLP promptly.